Compare Fubotv Inc (FUBO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Novartis AG — how do they compare? Fubotv Inc trades at $10.44 (market cap $302.39M), while Novartis AG trades at $152.4 (market cap $287.66B). The key difference: Novartis AG is far larger — about 951.3× Fubotv Inc's market cap, and Novartis AG pays a 3.14% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | NVS | |
|---|---|---|
Market Cap | $302.39M | $287.66B |
Sector | Technology | Health |
52-Week High | $54.72 | $168.62 |
52-Week Low | $8.09 | $113.50 |
Enterprise Value | $472.81M | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.54, down 2.95% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $172.25 million in 2024, but revenue grew to $1.62 billion, and profitability improved significantly in 2025 with a net income margin of 7.61%. Valuation ratios appear low, with a P/E of 2.67 and P/S of 0.21. Recent news highlights the appointment of a new CEO from Disney, sparking investor optimism about future growth.
The outlook is mixed; low valuations and a path to profitability present opportunity, but persistent cash flow challenges and high debt levels pose significant risks. Analyst consensus is a Buy with a $16.25 price target, suggesting substantial upside if the new leadership can execute on growth and monetization strategies effectively.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
